In this study, we designed a novel IgG-like bispecific antibody Y111, targeting both PD-L1 and CD3, on the format of Y-body® in which the anti-PD-L1 half antibody maintains its binding affinity to the PD-L1-positive tumor cells while the anti-CD3 scFv may reduce its binding affinity to the T cells (25, 26). This evidence concerns the gene CD274 and neoplasm.